Last reviewed · How we verify
hetrombopag
Hetrombopag, developed by Sun Yat-sen University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | hetrombopag |
|---|---|
| Also known as | SHR8735, Hetrombopag Olamine, Hetrombopag Olamine Tablets |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors (PHASE2)
- A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy (PHASE2)
- A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (PHASE3)
- Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma (NA)
- A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma (PHASE2)
- Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study (PHASE2)
- Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |